Patents by Inventor Zhongrui Zhang

Zhongrui Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEM AND METHOD FOR ADDITION AND SUBTRACTION IN MEMRISTOR-BASED IN-MEMORY COMPUTING
    Publication number: 20240127888
    Abstract: A method of measuring cross-correlation or similarity between input features and filters of neural networks using an RRAM-crossbar architecture to carry out addition/subtraction-based neural networks for in-memory computing. The correlation calculations use L1 norm operations of AdderNet. The RCM structure of the RRAM-cross bar has storage and computing collocated, such that processing is done in the analog domain with low power, low latency and small area. In addition, the impact due to the nonidealities of RRAM device can be alleviated by the implicit ratio-based feature of the structure.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Applicant: The University of Hong Kong
    Inventors: Yuan REN, Ngai WONG, Can LI, Zhongrui ZHANG
  • Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
    Patent number: 11059815
    Abstract: Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; methods of using the composition to inhibit neoplastic cell growth in mammals, including humans.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: July 13, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Weiping Tang, Ka Yang, Hao Wu, Zhongrui Zhang
  • SYNTHESIS OF SMALL MOLECULE HISTONE DEACETYLASE 6 DEGRADERS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20200190079
    Abstract: Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; methods of using the composition to inhibit neoplastic cell growth in mammals, including humans.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 18, 2020
    Inventors: Weiping Tang, Ka Yang, Hao Wu, Zhongrui Zhang